First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...
Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...
Plasmodium falciparum uses RIFIN proteins to bind to the inhibitory receptor KIR2DL1 on natural killer (NK) cells, thereby evading their attack. Conversely, NK cells can recognize RIFIN via the ...
Please provide your email address to receive an email when new articles are posted on . Allogeneic cell therapies help overcome challenges of autologous products, such as manufacturing complexity and ...
Immune-evading CAR-NK cells maintained a population in mice long enough to eliminate cancer whilst avoiding cytokine release syndrome. Massachusetts Institute of Technology (MIT) and Harvard Medical ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc., a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results